Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Evaluate ALG-010133 for the Treatment of Chronic Hepatitis B (CHB)

X
Trial Profile

A Phase II Study to Evaluate ALG-010133 for the Treatment of Chronic Hepatitis B (CHB)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALG 010133 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Aligos Therapeutics
  • Most Recent Events

    • 06 Jan 2022 According to an Aligos Therapeutics media release, the company and Study Review Committee (SRC) jointly concluded that data from phase 1 study were not sufficient to support further development of ALG-010133 and that dosing should be discontinued. The company has halted further development of ALG-010133 to address chronic hepatitis B.
    • 06 Jan 2022 Status changed from planning to withdrawn prior to enrolment, according to an Aligos Therapeutics media release.
    • 21 Jun 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top